Hormone-responsive breast cancers, ER+ (75·3 %) and PR+ (66·4 %) were the dominant breast cancer subtypes, while triple negative breast cancer accounted for 16·2 % (not stratified by menopausal status). This evidence concerns the gene PGR and triple-negative breast carcinoma.